基于β1-微管蛋白的巨核细胞成熟报告系统鉴定促进血小板生成的新药
研究构建了在TUBB1位点插入Venus报告基因的永生化巨核细胞系,用于高通量筛选促血小板样颗粒生成的化合物。筛选发现包括Wnt-C59在内的多种化合物通过拮抗芳香烃受体(AhR)提高血小板样颗粒产量,TCS 359则独立于FLT3和AhR发挥作用。该报告系统可用于研究血小板生成机制和筛选体外血小板生产诱导剂。
要点
- 构建TUBB1位点插入Venus的永生化巨核细胞报告系,可监测血小板样颗粒生成。
- 高通量筛选发现Wnt-C59等化合物通过拮抗AhR提高血小板样颗粒产量。
- TCS 359独立于FLT3或AhR显著增加血小板样颗粒生成。
核心结论
- 基于β1-微管蛋白的报告巨核细胞系是研究血小板生成机制和鉴定体外血小板生产新诱导剂的有用工具。
研究设计与样本
- 利用CRISPR/Cas9在永生化巨核细胞系(imMKCL)的TUBB1位点下游插入Venus转基因,构建报告细胞系并进行高通量药物筛选。
- 在无饲养层条件下评估化合物对血小板样颗粒(PLP)生成的影响,并在抗GPIbα抗体诱导的小鼠血小板减少模型中评估体内血小板恢复趋势。
主要发现
- 多种化合物在无饲养层条件下显著提高体外PLP生成效率,并在小鼠血小板减少模型中显示出恢复血小板的显著趋势。
- 包括WNT信号通路抑制剂Wnt-C59在内的多数化合物通过拮抗芳香烃受体(AhR)增加PLP生成。
- 针对AhR的小干扰RNA处理增加了Venus荧光强度和PLP生成。
- FLT3抑制剂TCS 359独立于FLT3或AhR显著增加PLP生成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During maturation, megakaryocytes (MKs) express β1-tubulin (TUBB1) and rearrange their microtubule components to enlarge, form proplatelets, and eventually release platelets. The development of a platform to identify in vitro conditions that would efficiently promote MK development could potentially enable large-scale platelet production. Here, we show that an immortalized MK cell line (imMKCL) genetically modified to express the β1-tubulin-Venus reporter provides a practical system to efficiently monitor the in vitro production of platelet-like particles (PLPs). The Venus transgene was inserted downstream of the TUBB1 locus in imMKCLs using CRISPR/Cas9, and the expression was visualized by Venus fluorescence intensity. This imMKCL reporter line was then used for high-throughput drug screening. We identified several compounds that significantly improved the efficiency of PLP production in vitro under feeder-free conditions and showed a significant tendency to recover platelets in vivo in a mouse thrombocytopenia model induced by anti-GPIbα antibody administration. Interestingly, most of these compounds, including a WNT signaling pathway inhibitor, Wnt-C59, antagonized the aryl hydrocarbon receptor (AhR) to increase PLP production, confirming the crucial role of AhR inhibition in MK maturation. Consistently, small interfering RNA treatment against AhR increased the Venus intensity and PLP production. TCS 359, an FLT3 inhibitor, significantly increased PLP production independently of FLT3 or AhR. This study highlights the usefulness of the β1-tubulin reporter MK line as a useful tool to study the mechanisms underlying thrombopoiesis and to identify novel inducers of ex vivo platelet production.
引用
- Seo H, Chen SJ, Hashimoto K, et al. A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Adv. 2018. PMID: 30206099. doi:10.1182/bloodadvances.2018019547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。